Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
D-Ribose is a naturally occurring pentose sugar used for energy restoration in cardiac and muscle tissue. It is generally well tolerated. It can lower blood glucose and should be monitored carefully in diabetic patients or those on blood-sugar medications. GI discomfort, headache, and lightheadedness are reported at high doses. Not recommended as a free sugar source for individuals with hereditary fructose intolerance.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Specialty
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for D-Ribose indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:07
Evidence Distribution
-
Observational / other LOW evidence YELLOWInflammaging-Induced Bioenergetic Gap Exhausts Pulmonary Nucleotide Pools to Exacerbate SARS-CoV-2 Outcomes in Early Stage Aging. ↗Li X et al.. Inflammaging-Induced Bioenergetic Gap Exhausts Pulmonary Nucleotide Pools to Exacerbate SARS-CoV-2 Outcomes in Early Stage Aging.. J Proteome Res. 2026. PMID:41870358.PMID 41870358 ↗Journal J Proteome ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41870358/
-
Observational / other LOW evidence YELLOWThiadiazole-azetidinone sulfonamide hybrids with antimycobacterial activity supported by structure-based analysis. ↗Vishwakarma SK et al.. Thiadiazole-azetidinone sulfonamide hybrids with antimycobacterial activity supported by structure-based analysis.. RSC Adv. 2026. PMID:41868340.PMID 41868340 ↗Journal RSC AdvYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41868340/
-
Observational / other LOW evidence YELLOWEffects of spironolactone on cytotoxic damage in osteoblasts. ↗Park SY et al.. Effects of spironolactone on cytotoxic damage in osteoblasts.. Exp Ther Med. 2026. PMID:41858771.PMID 41858771 ↗Journal Exp Ther MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858771/
-
Observational / other LOW evidence YELLOWPro-angiogenic small-diameter tissue-engineered vascular grafts (TEVGs) fabricated from 2-deoxy-D-ribose (2dDR)-incorporated electrospun polycaprolactone (PCL) fibers. ↗Filiz E et al.. Pro-angiogenic small-diameter tissue-engineered vascular grafts (TEVGs) fabricated from 2-deoxy-D-ribose (2dDR)-incorporated electrospun polycaprolactone (PCL) fibers.. Biomed Mater. 2026. PMID:41839165.PMID 41839165 ↗Journal Biomed MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41839165/
-
Observational / other LOW evidence YELLOWCoupled-enzyme assay for MTAP activity in biological samples. ↗Gilaj N et al.. Coupled-enzyme assay for MTAP activity in biological samples.. Anal Biochem. 2026. PMID:41825704.PMID 41825704 ↗Journal Anal BiochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41825704/
-
Observational / other LOW evidence YELLOWD-ribose-loaded hydrogel modulates necrosis progression and wound stability in a rabbit random-pattern skin flap model. ↗Rostami K et al.. D-ribose-loaded hydrogel modulates necrosis progression and wound stability in a rabbit random-pattern skin flap model.. JPRAS Open. 2026. PMID:41705265.PMID 41705265 ↗Journal JPRAS OpenYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41705265/
-
Observational / other LOW evidence YELLOWExploring the Natural Products Atlas (NPAtlas) Database for Hunting Prospective Irreversible Covalent DprE1 Inhibitors With Antitubercular Activity: An Integrated In-Silico Approach. ↗Ibrahim MAA et al.. Exploring the Natural Products Atlas (NPAtlas) Database for Hunting Prospective Irreversible Covalent DprE1 Inhibitors With Antitubercular Activity: An Integrated In-Silico Approach.. J Trop Med. 2026. PMID:41695983.PMID 41695983 ↗Journal J Trop MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41695983/
-
Observational / other LOW evidence YELLOWEnterococcus faecium secreted the NlpC/P60 family protein to enhance host immunity and indirectly increases Akkermansia muciniphila for slowing aging. ↗Guo Y et al.. Enterococcus faecium secreted the NlpC/P60 family protein to enhance host immunity and indirectly increases Akkermansia muciniphila for slowing aging.. Front Microbiol. 2026. PMID:41695942.PMID 41695942 ↗Journal Front MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41695942/
-
Observational / other LOW evidence YELLOWEffect of an integrated Yoga module on clinical, endocrine and metabolomic outcomes in polycystic ovarian syndrome. ↗Kumari D et al.. Effect of an integrated Yoga module on clinical, endocrine and metabolomic outcomes in polycystic ovarian syndrome.. J Ayurveda Integr Med. 2026. PMID:41679257.PMID 41679257 ↗Journal J Ayurveda Integr MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41679257/
-
Observational / other LOW evidence YELLOWD-ribose-induced cytotoxicity in K562 cells: RBKS-dependent disruption of copper homeostasis and mitochondrial function. ↗Zeying W et al.. D-ribose-induced cytotoxicity in K562 cells: RBKS-dependent disruption of copper homeostasis and mitochondrial function.. Free Radic Biol Med. 2026. PMID:41651301.PMID 41651301 ↗Journal Free Radic Biol MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41651301/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for D-Ribose. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for D-Ribose
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.